cing) in September 2012. In November 2013 the Principals invested S10rn at a valuation of S236tit post money. Other investors in the round included Decheng Capital and Stanford Startx. Schrodinger Schrodinger develops and sells leading computational drug design software applications for pharmaceutical and bio